Study of the influence of gender differences and comorbidities on calcified aortic stenosis. The Aldosterone pathway/mineralocorticoid receptor as a new therapeutic target. (Q3148687): Difference between revisions

From EU Knowledge Graph
Jump to navigation Jump to search
(‎Changed label, description and/or aliases in en: translated_label)
(‎Removed claim: summary (P836): Severe degenerative or calcified aortic stenosis (ACS) is a very prevalent disease, the incidence of which increases due to population ageing. There is no pharmacological treatment and aortic valve replacement is the only procedure that has shown an improvement in survival. Although the male sex is a risk factor for the development of CAD, information on gender-specific differences in valve pathology is scarce. Diabetes and renal dysfunction a...)
Property / summary
Severe degenerative or calcified aortic stenosis (ACS) is a very prevalent disease, the incidence of which increases due to population ageing. There is no pharmacological treatment and aortic valve replacement is the only procedure that has shown an improvement in survival. Although the male sex is a risk factor for the development of CAD, information on gender-specific differences in valve pathology is scarce. Diabetes and renal dysfunction are very common comorbidities in patients with CAD and influence their prognosis. The Aldosterone pathway/mineralocorticoid receptor (Aldo/MR) plays a role in diabetes and renal dysfunction although its role in CAD has not been studied. Currently, the pathophysiology of CAD is not well defined. The objective of this study is to investigate the pathophysiological differences in CAD in men and women and to analyse whether the Aldo/MR pathway could be a new therapeutic target in CAD and its associated comorbidities. Our main objectives will be: 1) Study the cellular and molecular differences in valvular alterations between men and women and identify new molecules responsible for these differences. 2) Analyse the effects of the Aldo/MR pathway on valve cells and its possible role as a therapeutic target in CAD in male and female animal models in the presence or absence of diabetes and kidney failure. 3) Investigate the expression pattern of fibrosis markers, calcification and new candidate molecules in the valves and serums of patients with CAD according to sex and presence of comorbidities. This project will lead to the study of the cellular and molecular mechanisms responsible for the pathophysiological differences of CAD in men and women, as well as to the analysis of the role that the Aldo/MR pathway can play in CAD, improving the options for individualising the measurement of CAD (English)
 
Property / summary: Severe degenerative or calcified aortic stenosis (ACS) is a very prevalent disease, the incidence of which increases due to population ageing. There is no pharmacological treatment and aortic valve replacement is the only procedure that has shown an improvement in survival. Although the male sex is a risk factor for the development of CAD, information on gender-specific differences in valve pathology is scarce. Diabetes and renal dysfunction are very common comorbidities in patients with CAD and influence their prognosis. The Aldosterone pathway/mineralocorticoid receptor (Aldo/MR) plays a role in diabetes and renal dysfunction although its role in CAD has not been studied. Currently, the pathophysiology of CAD is not well defined. The objective of this study is to investigate the pathophysiological differences in CAD in men and women and to analyse whether the Aldo/MR pathway could be a new therapeutic target in CAD and its associated comorbidities. Our main objectives will be: 1) Study the cellular and molecular differences in valvular alterations between men and women and identify new molecules responsible for these differences. 2) Analyse the effects of the Aldo/MR pathway on valve cells and its possible role as a therapeutic target in CAD in male and female animal models in the presence or absence of diabetes and kidney failure. 3) Investigate the expression pattern of fibrosis markers, calcification and new candidate molecules in the valves and serums of patients with CAD according to sex and presence of comorbidities. This project will lead to the study of the cellular and molecular mechanisms responsible for the pathophysiological differences of CAD in men and women, as well as to the analysis of the role that the Aldo/MR pathway can play in CAD, improving the options for individualising the measurement of CAD (English) / rank
Normal rank
 
Property / summary: Severe degenerative or calcified aortic stenosis (ACS) is a very prevalent disease, the incidence of which increases due to population ageing. There is no pharmacological treatment and aortic valve replacement is the only procedure that has shown an improvement in survival. Although the male sex is a risk factor for the development of CAD, information on gender-specific differences in valve pathology is scarce. Diabetes and renal dysfunction are very common comorbidities in patients with CAD and influence their prognosis. The Aldosterone pathway/mineralocorticoid receptor (Aldo/MR) plays a role in diabetes and renal dysfunction although its role in CAD has not been studied. Currently, the pathophysiology of CAD is not well defined. The objective of this study is to investigate the pathophysiological differences in CAD in men and women and to analyse whether the Aldo/MR pathway could be a new therapeutic target in CAD and its associated comorbidities. Our main objectives will be: 1) Study the cellular and molecular differences in valvular alterations between men and women and identify new molecules responsible for these differences. 2) Analyse the effects of the Aldo/MR pathway on valve cells and its possible role as a therapeutic target in CAD in male and female animal models in the presence or absence of diabetes and kidney failure. 3) Investigate the expression pattern of fibrosis markers, calcification and new candidate molecules in the valves and serums of patients with CAD according to sex and presence of comorbidities. This project will lead to the study of the cellular and molecular mechanisms responsible for the pathophysiological differences of CAD in men and women, as well as to the analysis of the role that the Aldo/MR pathway can play in CAD, improving the options for individualising the measurement of CAD (English) / qualifier
point in time: 12 October 2021
Timestamp+2021-10-12T00:00:00Z
Timezone+00:00
CalendarGregorian
Precision1 day
Before0
After0
 

Revision as of 15:08, 12 October 2021

Project Q3148687 in Spain
Language Label Description Also known as
English
Study of the influence of gender differences and comorbidities on calcified aortic stenosis. The Aldosterone pathway/mineralocorticoid receptor as a new therapeutic target.
Project Q3148687 in Spain

    Statements

    contained in NUTS
    Navarre
    0 references
    country
    Spain
    0 references
    EU contribution
    51,000.0 Euro
    0 references
    budget
    102,000.0 Euro
    0 references
    co-financing rate
    50.0 percent
    0 references
    start time
    1 January 2019
    0 references
    end time
    31 March 2022
    0 references
    beneficiary name (string)
    FUNDACION INSTITUTO DE INVESTIGACION SANITARIA DE NAVARRA
    0 references
    beneficiary
    Q3137938
    0 references
    coordinate location

    42°49'6.42"N, 1°38'39.34"W
    0 references
    postal code
    31201
    0 references
    summary
    La estenosis aórtica severa degenerativa o calcificada (EAC) es una enfermedad muy prevalente, cuya incidencia se incrementa debido al envejecimiento de la población. No existe tratamiento farmacológico y el recambio valvular aórtico es el único procedimiento que ha demostrado una mejoría de la supervivencia. Aunque el sexo masculino es un factor de riesgo para el desarrollo de la EAC, la información de las diferencias en función del género específicas en la patología valvular es escasa. La diabetes y la disfunción renal son comorbilidades muy frecuentes en los pacientes con EAC e influencian su pronóstico. La vía de la Aldosterona/receptor mineralocorticoide (Aldo/MR) juega un papel en la diabetes y en la disfunción renal aunque su papel en la EAC no ha sido estudiado. Actualmente la fisiopatología de la EAC no está bien definida. El objetivo de este estudio es investigar las diferencias fisiopatológicas de la EAC en hombres y en mujeres y analizar si la vía Aldo/MR podría ser una nueva diana terapéutica en la EAC y en sus comorbilidades asociadas. Nuestros objetivos principales serán: 1) Estudiar las diferencias celulares y moleculares en las alteraciones valvulares entre hombres y mujeres e identificar nuevas moléculas responsables de estas diferencias. 2) Analizar los efectos de la vía Aldo/MR en células de válvula y su posible papel como diana terapéutica en la EAC en modelos animales machos y hembras en presencia o ausencia de diabetes e insuficiencia renal. 3) Investigar el patrón de expresión de marcadores de fibrosis, calcificación y de nuevas moléculas candidatas en las válvulas y sueros de pacientes con EAC en función de sexo y presencia de comorbilidades. Este proyecto llevará al estudio de los mecanismos celulares y moleculares responsables de las diferencias fisiopatológicas de la EAC en hombres y en mujeres, así como al análisis del papel que la vía Aldo/MR puede desarrollar en la EAC, mejorando las opciones para individualizar el ttmiento de la EAC (Spanish)
    0 references
    location (string)
    Pamplona/Iruña
    0 references

    Identifiers

    Spanish Kohesio ID
    PI18_01875
    0 references
     
    Retrieved from "https://linkedopendata.eu/w/index.php?title=Item:Q3148687&oldid=12807080"